Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved tags : Vaccine save search
CORBEVAX®, A COVID19 VACCINE DEVELOPED BY BIO E-INDIA BASED ON THE RBD PROTEIN ANTIGEN TECHNOLOGY FROM TEXAS CHILDREN'S HOSPITAL CENTER FOR VACCINE DEVELOPMENT, RECEIVES WORLD HEALTH ORGANIZATION EMERGENCY USE LISTING APPROVAL
Published: 2024-01-22 (Crawled : 18:00) - prnewswire.com
OVV | $51.53 -0.43% 0.0% 2M
|
Energy Minerals
|
| O: -0.49%
H: 1.94%
C: 1.42%
covid19 corbevax vaccine health world approval hospital protein technology
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
Published: 2023-11-28 (Crawled : 13:00) - prnewswire.com
QURE | $4.71 0.86% 0.85% 440K
|
Health Technology
|
| O: -3.42%
H: 3.24%
C: 2.95%
ARCT 4 | $26.31 -4.81% -5.06% 610K
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: -0.93%
arct-154 covid vaccine approved mrna
Novavax's Updated COVID-19 Vaccine Now Approved in the EU
Published: 2023-10-31 (Crawled : 21:00) - prnewswire.com
NVAX | $3.9 0.26% 0.26% 2.8M
|
Health Technology
|
| O: 0.6%
H: 5.22%
C: 4.48%
covid-19 vaccine approved
Novavax's Prototype COVID-19 Vaccine Nuvaxovid™ Receives Full Approval in Singapore
Published: 2023-10-18 (Crawled : 13:30) - biospace.com/
NVAX | $3.9 0.26% 0.26% 2.8M
|
Health Technology
|
| O: -0.78%
H: 2.5%
C: 1.09%
covid-19 vaccine prototype approval
FDA Panel Sets Possible Precedent; Novavax Wins Approval for Updated COVID-19 Vaccine
Published: 2023-10-05 (Crawled : 15:30) - biospace.com/
PRGO | $29.94 -0.33% 0.0% 970K
|
Health Technology
|
| O: 0.4%
H: 2.05%
C: 1.82%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
covid-19 fda vaccine approval
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
Published: 2023-09-11 (Crawled : 20:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.03%
H: 0.18%
C: -0.88%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.65%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 570K
|
Health Technology
|
| O: -0.49%
H: 0.2%
C: -1.33%
covid-19 fda vaccine approval
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine
Published: 2023-09-11 (Crawled : 20:00) - biospace.com/
MRNA | News S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -0.78%
H: 0.42%
C: -0.94%
covid-19 fda vaccine approval
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age
Published: 2023-08-21 (Crawled : 00:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.14%
H: 1.3%
C: 0.82%
fda active vaccine respiratory virus
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
Published: 2023-07-20 (Crawled : 22:00) - globenewswire.com
EBS | $1.86 -2.11% 0.0% 1.1M
|
Health Technology
|
| O: 7.22%
H: 4.76%
C: -0.79%
av7909 fda anthrax vaccine approval
YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA
Published: 2023-06-01 (Crawled : 13:00) - biospace.com/
YS | $0.87 -7.05% -7.59% 350K
|
n/a
|
| O: 5.96%
H: 10.63%
C: 4.38%
fda vaccine approval trial
YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan
Published: 2023-05-16 (Crawled : 13:00) - biospace.com/
YS | $0.87 -7.05% -7.59% 350K
|
n/a
|
| O: 13.71%
H: 0.0%
C: -14.18%
vaccine approval trial pakistan
US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
Published: 2023-05-03 (Crawled : 23:00) - biospace.com/
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 1.24%
H: 1.14%
C: 0.11%
AGEN | News | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 1.42%
H: 6.99%
C: 4.2%
fda vaccine respiratory virus
U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
Published: 2023-04-27 (Crawled : 22:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.03%
H: 0.54%
C: 0.31%
fda pneumococcal children vaccine
Summit stockholders approve merger with vaccine maker YishengBio – Seeking Alpha
Published: 2023-03-15 (Crawled : 13:00) - spacfeed.com
ARKO | $4.5 0.45% 0.44% 550K
|
|
| O: -2.01%
H: 2.29%
C: 2.17%
MHLD | $1.945 -3.23% -3.34% 160K
|
Finance
|
| O: -5.62%
H: 5.11%
C: -4.26%
vaccine
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
Published: 2023-02-28 (Crawled : 00:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.69%
H: 0.52%
C: 0.17%
fda candidate vaccine rsv approval potential positive
GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate
Published: 2023-02-01 (Crawled : 14:00) - biospace.com/
GRNA | $0.2995 -0.03% -0.07% 0
|
Professional, Scientific, and T...
|
| O: 6.24%
H: 0.0%
C: -5.87%
covid-19 candidate vaccine mrna trial approval
J&J Shuts Down Second HIV Vaccine Trial in as Many Years
Published: 2023-01-19 (Crawled : 14:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.43%
H: 1.33%
C: 0.3%
vaccine hiv trial
Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster
Published: 2023-01-18 (Crawled : 14:20) - biospace.com/
NVAX | $3.9 0.26% 0.26% 2.8M
|
Health Technology
|
| O: 1.53%
H: 8.47%
C: -1.19%
covid-19 vaccine approved nuvaxovid
Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines Jiangsu Recbio Technology Co., Ltd. is pleased to announce that, the Group has recently...
Published: 2022-12-19 (Crawled : 07:00) - biospace.com/
MDGL M | $222.18 -2.7% -2.8% 270K
|
Health Technology
|
| O: 219.37%
H: 0.0%
C: 0.0%
rec610 vaccine technology trial approval group
VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults
Published: 2022-12-08 (Crawled : 15:20) - biospace.com/
VBIV | $0.6001 -1.46% -1.48% 180K
|
Health Technology
|
| O: 0.79%
H: 12.25%
C: 2.24%
hepatitis canada health approval vaccine
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
AGBA | $1.02 155.0% 60.78% 120M
|
Finance
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 900K
|
OST | $0.499 21.38% 45.26% 1.9M
|
ZCMD | $2.44 78.1% 43.85% 330K
|
Commercial Services
XPON | $3.1 60.62% 37.74% 16M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.